Alpha Tau Medical Ltd

NASDAQ DRTS

Data sourced from

and

Daily

Download Data

Alpha Tau Medical Ltd Price to Sales Ratio (P/S) on June 03, 2024

Alpha Tau Medical Ltd Price to Sales Ratio (P/S) is NA on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.

Alpha Tau Medical Ltd 52-week high Price to Sales Ratio (P/S) is NA on June 03, 2024, which is NA below the current Price to Sales Ratio (P/S).
Alpha Tau Medical Ltd 52-week low Price to Sales Ratio (P/S) is NA on June 03, 2024, which is NA below the current Price to Sales Ratio (P/S).
Alpha Tau Medical Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is NA.

NASDAQ: DRTS

Alpha Tau Medical Ltd

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street, Jerusalem, Israel, 9777605
Employees	121
Sector	Healthcare
Industry	Biotechnology

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends